Abbreviations: 2-yrs pSU = P-value of 2-year survival; DOD = dead of disease; HSCT = hematopoietic stem cell transplantation; ICU = intensive care unit; MAC = myeloablative conditioning; MBL = mannan-binding lectin; RIC = reduced intensity conditioning; susp = suspected; TRM = transplant-related mortality. For classification of MBL genotypes, see Supplementary Information. The P-value for survival analysis, MAC and RIC indicates the significance value comparing entire survival curves calculated by the use of log-rank test. The P-value for MBL genotype groups indicates the significance value comparing MBL high/ medium versus low/very low groups.
but profound state of immunodeficiency, low MBL levels or particular MBL genotypes are reported to contribute to and increase the rate of transplant-related infections.
In consideration of the so far inconsistent findings of the role of MBL in HSCT in adult, [2] [3] [4] [5] as well as pediatric 6 HSCT, we prospectively investigated the impact of MBL levels, genotypes and MASP-2 levels in a series of 99 pediatric (n = 96) and young adult (n = 3) HSCT recipients. MBL deficiency was defined by MBL levels o 300 ng/mL and/or particular MBL haplotypes. Patient characteristics, MBL genotype data and corresponding MBL levels are summarized in the Supplementary Information together with MASP-2 serum levels and statistical analyses.
RESULTS
The P of a 2-year overall survival (2-yrs pSU) of the entire cohort of 99 transplant recipients was 67%. We found that neither low MBL serum levels nor MBL genotypes that are usually linked with a low serum level or decreased protein function 1 were associated with a poor outcome (Table 1) .
We also did not note any increased risks for bacterial, viral or fungal infections in MBL deficient patients that would have required their admission to intensive care units within a 100 day post-transplantation period (Table 1) . Setting the threshold to o500 ng mL −1 equally failed to show any negative impact. These observations are in line with those obtained in a similar previous study of pediatric HSCT patients, in which MBL levels of o400 ng/mL were also not associated with an increased infection rate. 6 The findings in studies investigating adult-HSCT recipients, on the other hand, are inconsistent. In those, low MBL levels had either no effect on the risk of infection 3 or, they had even a negative impact on the infection risk under particular circumstances, for instance in case of TBI. 2, 4 The uniform finding was that in neither of the studies, like in ours, MBL low serum levels and/or MBL particular genotypes affected the ultimate outcome.
However, the novel and most intriguing finding in the present study is the significantly reduced rate of acute GvHD (aGvHD) in MBL deficient patients, irrespective of whether MBL deficiency was defined by serum levels or genotypes (Figures 1a and b) . Of the 12 patients with MBL levels ⩽ 300 ng/mL, only 2 developed mild (grade I-II) aGvHD. In contrast, 46/76 (61%) patients with MBL levels of 4300 ng/mL developed aGvHD, 37 (48%) of them grade I-II and 9 (12%) grade III-IV aGvHD (P = 0.005). Moreover, the P-value of aGvHD was also significantly lower (P = 0.008) in the combined genotype-defined low and very low level MBL groups than in the medium/high genotype ones. Univariate analyses of relevant transplant-related GVHD risk variables revealed that the use of serotherapy and reduced intensity conditioning (RIC), which was almost exclusively used in patients with non-malignant diseases, were associated with a decreased risk of GvHD (Figure 1c and Supplementary Information). Apart from RIC regimen, MBL levels of ⩽ 300 ng/mL was the only parameter that remained statistically valid in a multivariate model of logistic regression analysis (Figure 1d) .
The finding of a statistically significant inverse correlation of low MBL levels and the incidence and severity of aGvHD may suggest a substantial role of MBL-mediated Cʹ activation in the pathophysiology of GvHD. There is indeed accumulating evidence for a prominent function of Cʹ activation in allo-reactivity.
A reduced Cʹ activation was proposed previously to be an important factor in the ameliorated risk of transplant rejection in MBL deficient patients receiving solid organs, such as kidney, heart and lung. 7 Allo-reactivity is understood to be an inflammatory process with ensuing Cʹ activation that enhances the extent of tissue damage. This view of MBL's role in inflammatory processes is also corroborated by the better outcome of MBL deficient patients with ischemic events, such as myocardial infarction or ischemic stroke, in which reduced collateral tissue injury on the basis of reduced Cʹ activation was suggested to co-determine the better course and final outcome. 7, 8 Along this line of argument, a substantial role of Cʹ activation in GvHD has also been supported experimentally in a murine HSCT model. Cʹ deficient mice were found to have a significantly reduced GvHD-associated morbidity and mortality, 9 most likely because of a diminished Th1/Th17 polarization upon Cʹ inhibition, recently also shown in human T-cells. 10 In human HSCT, both the conditioning regimen and the invasion of donor allo-reactive T-cells into target tissues have an effect on the extent of tissue injury and Cʹ activation. The binding of MBL to apoptotic and necrotic cells 11 in the process of clearing damaged cells may enhance Cʹ activation and thus contribute to GvHD severity. Conversely, both low MBL levels, as well as specific MBL genotypes, in which the altered secondary structure of the collagenous region of MBL weakens MBL binding to MASPs, result in an impaired activation of the lectin pathway (reviewed in ref. 1) and might reduce the development and progression of GvHD.
Taken together, MBL deficiency appears to be beneficial in diseases in which the pathology is driven by Cʹ activation that aggravates tissue damage. Although the limited number of patients together with the heterogenous transplant procedures do not allow us to draw a final conclusion about the specific contribution of MBL in this setting, low MBL levels do not seem to increase the risk of severe infections in the immediate posttransplantation period of pediatric and young adult-HSCT recipients, but rather diminish the rate and severity of aGvHD.
Although the biological and clinical effects of MBL deficiency in HSCT clearly deserve further investigation, all data available so far clearly argue against the previously suggested prophylactic MBL replacement in HSCT.
